PL2943488T3 - Postacie soli megluminowej kwasu 2-((1r,4r)-4-(4-(5-(benzoksazol-2-iloamino)pirydyn-2-ylo)fenylo)cykloheksylo)octowego i ich zastosowania jako inhibitory dgat1 - Google Patents

Postacie soli megluminowej kwasu 2-((1r,4r)-4-(4-(5-(benzoksazol-2-iloamino)pirydyn-2-ylo)fenylo)cykloheksylo)octowego i ich zastosowania jako inhibitory dgat1

Info

Publication number: PL2943488T3
Authority: PL; Poland
Prior art keywords: benzoxazol; ylamino; pyridin; cyclohexyl; phenyl
Prior art date: 2013-01-11

Application number

PL14701273T

Other languages

English (en)

Inventor

Christina Capacci-Daniel

Marilyn DELACRUZ

Baoqing Gong

Akash Jain

Yansong Lu

Lijun Zhang

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-01-11

Filing date

2014-01-10

Publication date

2018-09-28

2014-01-10 Application filed by Novartis Ag filed Critical Novartis Ag

2018-09-28 Publication of PL2943488T3 publication Critical patent/PL2943488T3/pl

Links

QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 title 3
229940127193 DGAT1 inhibitor Drugs 0.000 title 1
MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical group CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 title 1
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Diabetes (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Hematology (AREA)
Obesity (AREA)
Epidemiology (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Rheumatology (AREA)
Vascular Medicine (AREA)
Child & Adolescent Psychology (AREA)
Pain & Pain Management (AREA)
Urology & Nephrology (AREA)
Physical Education & Sports Medicine (AREA)
Hospice & Palliative Care (AREA)
Gastroenterology & Hepatology (AREA)
Dermatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

PL14701273T 2013-01-11 2014-01-10 Postacie soli megluminowej kwasu 2-((1r,4r)-4-(4-(5-(benzoksazol-2-iloamino)pirydyn-2-ylo)fenylo)cykloheksylo)octowego i ich zastosowania jako inhibitory dgat1 PL2943488T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201361751443P	2013-01-11	2013-01-11
EP14701273.6A EP2943488B1 (en)	2013-01-11	2014-01-10	Meglumine salt forms of 2-((1 r,4r)-4-(4-(5-(benzoxazol-2-ylamino)pyridin-2-yl)phenyl)cyclohexyl) acetic acid and their use as dgat1 inhibitors
PCT/US2014/011005 WO2014110344A1 (en)	2013-01-11	2014-01-10	Meglumine salt forms of 2-((1 r,4r)-4-(4-(5-(benzoxazol-2-ylamino)pyridin-2-yl)phenyl)cyclohexyl) acetic acid and their use as dgat1 inhibitors

Publications (1)

Publication Number	Publication Date
PL2943488T3 true PL2943488T3 (pl)	2018-09-28

Family

ID=50001335

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL14701273T PL2943488T3 (pl)	2013-01-11	2014-01-10	Postacie soli megluminowej kwasu 2-((1r,4r)-4-(4-(5-(benzoksazol-2-iloamino)pirydyn-2-ylo)fenylo)cykloheksylo)octowego i ich zastosowania jako inhibitory dgat1

Country Status (16)

Country	Link
US (2)	US8987459B2 (pl)
EP (1)	EP2943488B1 (pl)
JP (1)	JP6302937B2 (pl)
KR (1)	KR20150103747A (pl)
CN (1)	CN104995188B (pl)
AR (1)	AR101523A1 (pl)
AU (1)	AU2014205276B2 (pl)
BR (1)	BR112015016370A2 (pl)
CA (1)	CA2896861A1 (pl)
EA (1)	EA027688B1 (pl)
ES (1)	ES2675398T3 (pl)
MX (1)	MX2015008978A (pl)
PL (1)	PL2943488T3 (pl)
PT (1)	PT2943488T (pl)
TR (1)	TR201808198T4 (pl)
WO (1)	WO2014110344A1 (pl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2896861A1 (en) *	2013-01-11	2014-07-17	Novartis Ag	Meglumine salt forms of 2-((1r,4r)-4-(4-(5-(benzoxazol-2-ylamino)pyridin-2-yl)phenyl)cyclohexyl) acetic acid and their use as dgat1 inhibitors
KR101684053B1 (ko) *	2015-01-20	2016-12-08	씨제이헬스케어 주식회사	벤즈이미다졸 유도체의 신규 결정형 및 이의 제조방법
CA3097384A1 (en) *	2018-04-17	2019-10-24	Cardurion Pharmaceuticals, Llc	Meglumine salts of thienopyrimidines
MX2023005447A (es) *	2020-11-10	2023-09-25	Unity Biotechnology Inc	Inhibidor de sales sólidas cristalinas de meglumina de bcl y métodos de elaboración y uso de estos.

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TW200303742A (en)	2001-11-21	2003-09-16	Novartis Ag	Organic compounds
EP2402317B1 (en)	2006-03-31	2013-07-03	Novartis AG	DGAT inhibitor
WO2013169648A1 (en) *	2012-05-07	2013-11-14	Novartis Ag	Pharmaceutical combinations comprising a dgat1 inhibtor and a triglyceride lowering drug
CA2896861A1 (en) *	2013-01-11	2014-07-17	Novartis Ag	Meglumine salt forms of 2-((1r,4r)-4-(4-(5-(benzoxazol-2-ylamino)pyridin-2-yl)phenyl)cyclohexyl) acetic acid and their use as dgat1 inhibitors

2014
- 2014-01-10 CA CA2896861A patent/CA2896861A1/en not_active Abandoned
- 2014-01-10 PL PL14701273T patent/PL2943488T3/pl unknown
- 2014-01-10 EA EA201591300A patent/EA027688B1/ru not_active IP Right Cessation
- 2014-01-10 AU AU2014205276A patent/AU2014205276B2/en not_active Ceased
- 2014-01-10 ES ES14701273.6T patent/ES2675398T3/es active Active
- 2014-01-10 PT PT147012736T patent/PT2943488T/pt unknown
- 2014-01-10 WO PCT/US2014/011005 patent/WO2014110344A1/en not_active Ceased
- 2014-01-10 US US14/152,282 patent/US8987459B2/en not_active Expired - Fee Related
- 2014-01-10 EP EP14701273.6A patent/EP2943488B1/en not_active Not-in-force
- 2014-01-10 KR KR1020157021323A patent/KR20150103747A/ko not_active Ceased
- 2014-01-10 JP JP2015552797A patent/JP6302937B2/ja not_active Expired - Fee Related
- 2014-01-10 MX MX2015008978A patent/MX2015008978A/es unknown
- 2014-01-10 CN CN201480003867.0A patent/CN104995188B/zh not_active Expired - Fee Related
- 2014-01-10 BR BR112015016370A patent/BR112015016370A2/pt not_active IP Right Cessation
- 2014-01-10 TR TR2018/08198T patent/TR201808198T4/tr unknown
- 2014-01-13 AR ARP140100113A patent/AR101523A1/es unknown
2015
- 2015-02-24 US US14/630,624 patent/US9242971B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
EA201591300A1 (ru)	2015-11-30
EA027688B1 (ru)	2017-08-31
PT2943488T (pt)	2018-06-12
US8987459B2 (en)	2015-03-24
CA2896861A1 (en)	2014-07-17
MX2015008978A (es)	2015-09-29
EP2943488A1 (en)	2015-11-18
BR112015016370A2 (pt)	2017-07-11
US20150166522A1 (en)	2015-06-18
AU2014205276A1 (en)	2015-07-16
AU2014205276B2 (en)	2016-10-20
US9242971B2 (en)	2016-01-26
ES2675398T3 (es)	2018-07-11
WO2014110344A1 (en)	2014-07-17
TR201808198T4 (tr)	2018-07-23
CN104995188B (zh)	2018-09-14
CN104995188A (zh)	2015-10-21
US20140200246A1 (en)	2014-07-17
JP2016505017A (ja)	2016-02-18
EP2943488B1 (en)	2018-03-28
AR101523A1 (es)	2016-12-28
KR20150103747A (ko)	2015-09-11
JP6302937B2 (ja)	2018-03-28

Similar Documents

Publication	Publication Date	Title
IL267090A (en)	2019-08-29	Amine-disubstituted heterocyclic compounds as ehmt2 inhibitors and methods of using them
IL257390B (en)	2022-06-01	Salts of 1-((4-methoxymethyl)-4-(((s2,r1)-2-phenyl-cyclopropylamine)methyl)piperidine-1-yl)methyl)-cyclobutane-carboxylic acid as lsd1 inhibitors
NZ627586A (en)	2016-08-26	Pyridone derivatives
IL229395A0 (en)	2014-01-30	Modified release of4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-5-(4-methyl-1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl]benzamide solubilized using organic acids
PL3290414T3 (pl)	2020-01-31	Sposób otrzymywania n-[5-(3,5-difluorobenzylo)-1h-indazol-3-ilo]-4-(4-metylopiperazyn-1-ylo)-2-(tetrahydropiran-4-yloamino)benzamidu
LT2806859T (lt)	2019-10-25	3-(6-(1-(2,2-difluorbenzo[d][1,3]dioksol-5-il) ciklopropankarboksamido)-3-metilpiridin-2-il)benzenkarboksirūgšties kompozicijos
ZA201101891B (en)	2012-05-30	The salts of n-[4-(1-cyanocyclopentyl)phenyl]-2-(4-pyridyl methyl)amino-3-pyridinecarboxamide
PL2625175T3 (pl)	2016-04-29	Krystaliczny ((R)-(E)-2-(4-(2-(5-(1-(3,5-dichloropirydyn-4-ylo)etoksy)-1H-indazol-3-ilo)winylo)-1H-pirazol-1-ilo)etanol i jego zastosowanie jako inhibitora FGFR
EP2673269A1 (en)	2013-12-18	Heterocyclic compounds as pi3 kinase inhibitors
PT2987791T (pt)	2019-10-24	Derivado de ácido 3-(4-(benziloxi)fenil)hex-4-inoico, adequado para prevenção e tratamento de doenças metabólicas.
IL251818B (en)	2021-01-31	Crystalline forms of 5-chloro-n4-[2-(dimethylphosphoryl)phenyl]-n2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]pyrimidine-2,4-diamine
PH12015500678A1 (en)	2015-05-18	Crystalline forms of a factor xia inhibitor
SMT201800289T1 (it)	2018-07-17	Ammidi eterocicliche come inibitori di chinasi
HUE041725T2 (hu)	2019-05-28	(S)-1-(2-hidroxietil)-4-metil-N-[4-(metilszulfonil)fenil]-5-[2-(trifluormetil)fenil]-1H-pirrol-3-karboxamid kristálya
PL3059227T3 (pl)	2019-11-29	Sól heterocyklicznego związku zawierającego azot lub jej kryształ, kompozycja farmaceutyczna i inhibitor flt3
IL234742A0 (en)	2014-11-30	Salts of 5-[(2,21)]4]-2})-2-(r-difluoro-2-phenylethoxy)phenyl]ethyl}amino)-1-hydroxyethyl]-8-hydroxyquinoline-2(1h)- potency
IL273974A (en)	2020-05-31	Amine-Disubstituted Heterocyclic Compounds as EHMT2 Inhibitors, Their Salts, and Method for Their Synthesis
IL243913A0 (en)	2016-04-21	2-[5-[n-(4-fluorophenyl)carbamoyl]pyrimidine-2-ylsulfonylmethyl]-4-(trifluoromethoxy)phenyl]boronic acid
ZA202003028B (en)	2021-08-25	Novel use of 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative
PT2943488T (pt)	2018-06-12	Formas de sal de meglumina do ácido 2-((1r,4r)-4-(4-(5- (benzoxazol-2-ilamina)piridin-2-il)fenil)ciclohexil) acético e sua utilização como inibidores de dgat1
ZA201402756B (en)	2015-04-29	Immediate release 4-methyl-3-[[4-(3-pyridinyl)]amino]-n-[5-(4-methyl- 1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl]benzamide formulation
SG11201604940VA (en)	2016-07-28	N1-(3,3,3-trifluoro-2-hydroxo-2-methylpropionyl)-piperidine derivatives as inhibitors of pyruvate dehydrogenase kinase
SI2608789T1 (sl)	2017-06-30	Terapevtske uporabe 1-(2-(2,4-dimetil-fenilsulfanil) fenil) piperazina
SG11201604517WA (en)	2016-07-28	Crystalline forms of n-(4-((3-(2-amino-4-pyrimidinyl) - 2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1 -phthalazinamine pharmaceutically acceptable salts and uses thereof
IL263786B (en)	2022-05-01	Crystalline forms of 4-(5-(7,4-dimethylbenzofuran-2-yl)-4,2,1-oxadiazol-3-yl)benzoic acid and processes for their preparation